Skip to main content

Arhalofenate, URAT-1 Inhibitor, Being Developed for Gout

Good news for gout patients includes the recent approval of Zurampic (lesinurad), a URAT-1 inhibitor, and that effective urate-lowering therapy has significant long-term cardiovascular benefits. 

Fortunately, new drug development continues, including arhalofenate, a novel anti-inflammatory uricosuric. This agent's efficacy is based on being a URAT-1 inhibitor (blocks uric readsorbtion at the proximal tubule) and is also an anti-inflammatory drug.

A 12-week, randomized, controlled trial of 239 hyperuricemic gout patients (with recurrent flares) received daily arhalofenate 600 or 800 mg, allopurinol 300 mg, allopurinol 300 mg + 0.6 mg colchicine or placebo. The primary outcome was the flare incidence at 12 weeks.

The arhalofenate 800 mg had 46% fewer flares compared to allopurinol 300 mg (0.66 versus 1.24, p = 0.0056).  Arhalofenate 800 mg was also significantly better than placebo (p = 0.049), but did not achieve significance compared to allopurinol + colchicine (p = 0.091).

Serum urate significantly decreased -12.5% and -16.5% with arhalofenate 600 mg and 800 mg (p = 0.001 and p=0.0001) more than placebo. Adverse events were not different between groups. 

Arhalofenate appears to be an effective urate-lowering therapy and has shown to be more effective at decreasing gout flares compared to allopurinol.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject